THE BILLION-DOLLAR PROBLEM KEEPING OZEMPIC, WEGOVY, AND ZEPBOUND FROM PATIENTS

Researchers have identified a significant issue with the funding of Ozempic, Wegovy, and similar drugs, which may have excellent health benefits but could overwhelm insurance budgets if covered for millions of eligible patients. According to Health & Medicine News -- Scienc, the high cost of these medications poses a major problem. This has led to concerns about the accessibility of these treatments for those who need them.

The concern is that the high cost of these medications may lead to patients seeking low-cost, compounded versions, which could carry serious safety risks, as noted by researchers. There is limited information available on the exact costs and numbers of patients affected, but the issue highlights the need for better long-term support for these medications. Additionally, other sources have reported on potential side effects and benefits of these medications, such as hair loss risk and the ability to quiet the brain's food craving circuit.

The issue of funding for Ozempic, Wegovy, and similar drugs is significant because it affects the accessibility of these potentially life-changing treatments for millions of people, and highlights the need for sustainable and safe solutions to support patient care.

• Ozempic, Wegovy, and similar drugs may be too expensive for insurance budgets
• Low-cost, compounded versions may carry serious safety risks
• Researchers highlight the need for better long-term support for these medications

Read the original source for full detail available at Health & Medicine News -- Scienc src